Prostate Cancer Clinical Trial
Axumin PETMRI Imaging Following Focal Cryo-ablation (FCA)
Summary
This is a prospective outcomes study assessing quality of life and oncological control at pre-defined time points following FOCAL CRYO-ABLATION (FCA). The investigator's standard of care is to perform an Magentic Resonance Imaging (MRI) and prostate biopsy two years following FCA. The prostate biopsy assesses both the presence of in field and out of field disease. The role of Axumin PET/MRI for detecting disease following FCA has not been previously examined.
Full Description
The primary hypothesis of this study is that 18F-Fluciclovine PET/MRI imaging at two years following FCA will improve sensitivity for detection of in field recurrence of significant prostate cancer defined as any Gleason pattern 4 disease.
The secondary hypothesis of this study is that 18F-Fluciclovine PET/MRI imaging at two years following FCA will improve sensitivity for detection of out of field recurrence of significant prostate cancer .
Eligibility Criteria
Inclusion Criteria:
FCA at NYU Langone Health performed at least two years prior to study enrollment by Drs. Lepor or Wysock.
No prostate cancer specific treatment following FCA
Consented to undergo reflex MRI and prostate biopsy two years following FCA.
Exclusion Criteria:
Any contraindication to prostate biopsy
Prior allergic reaction to 18F-Fluciclovine
Patient refuses MRI and prostate biopsy two years following FCA.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10016, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.